Adding Keytruda (pembrolizumab) to standard first-line chemotherapy significantly extends the survival of people with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) cancer, and also significantly lowers their risk of disease progression or death, according to interim data from a Phase 3 trial.
Keytruda Combo Shown to Extend Survival in Advanced Esophageal, GEJ Cancers